Clinical Trials
8
Active:0
Completed:0
Trial Phases
3 Phases
Early Phase 1:1
Phase 1:6
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Phase 1
6 (75.0%)Early Phase 1
1 (12.5%)Not Applicable
1 (12.5%)A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR201 in the Treatment of Subjects With Parkinson's Disease
Phase 1
Not yet recruiting
- Conditions
- Parkinson Disease
- Interventions
- Drug: Allogeneic dopaminergic neural precursor cell(NCR201)
- First Posted Date
- 2025-05-18
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Nuwacell Biotechnologies Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT06978920
- Locations
- 🇨🇳
The First Affiliated Hospital of USTC, Hefei, Anhui, China
A Trial to Evaluate the Safety and Efficacy of NCR102 in Subjects With aGVHD
Phase 1
Not yet recruiting
- Conditions
- Acute Graft-versus-Host Disease
- Interventions
- Biological: NCR102 injection
- First Posted Date
- 2025-04-23
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Nuwacell Biotechnologies Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT06941350
A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR101 in the Treatment of Subjects With Interstitial Lung Disease
Phase 1
Not yet recruiting
- Conditions
- Interstitial Lung Disease (ILD)
- Interventions
- First Posted Date
- 2025-02-13
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Nuwacell Biotechnologies Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT06825169
A Study of NCR100 Injection for the Treatment of Knee Osteoarthritis（ KOA）
Phase 1
Not yet recruiting
- Conditions
- Knee Osteoarthritis
- Interventions
- Other: 0.9% Normal saline
- First Posted Date
- 2024-12-18
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Nuwacell Biotechnologies Co., Ltd.
- Target Recruit Count
- 162
- Registration Number
- NCT06741098
A Trial to Evaluate the Safety and Efficacy of NCR300 in Preventing Recurrence of Acute Myeloid Leukemia（AML) After Transplantation
Phase 1
Not yet recruiting
- Conditions
- Acute Myeloid Leukemia
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Nuwacell Biotechnologies Co., Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT06441084
- Prev
- 1
- 2
- Next
News
No news found